Fran Curtis is a five-time survivor of cancers survivor including breast, appendix and skin cancer, but she told CURE in a ...

The potential of moving the combination to the earlier MIBC setting significantly increases the Padcev market.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced landmark results demonstrating ...

The NIAGARA trial showed that adding durvalumab to neoadjuvant chemotherapy in MIBC patients did not negatively impact HRQOL outcomes. Significant improvement in event-free survival was observed with ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

CG Oncology Inc. (NASDAQ:CGON) is one of the best hot stocks to invest in. On October 8, Guggenheim analyst Brad Canino ...

Inlexzo is supplied as a single-dose intravesical system containing 225mg of gemcitabine plus a sterile urinary catheter and stylet.

To our knowledge, SunRISe-4 shows, for the first time, a benefit of the addition of the localised TAR-200 gemcitabine intravesical system to systemic checkpoint inhibition as neoadjuvant treatment in ...

Dr. Kates’ experience as chair of the landmark Phase 3 BRIDGE bladder cancer trial and dedication to patient care will be invaluable to the ...

The FDA approved the system in September 2025. A novel drug-delivery system has demonstrated effectiveness in treating specific bladder cancer patients whose tumors previously did not respond to ...

When treating patients with bladder cancer using gemcitabine intravesical system, regular AE monitoring is necessary, said Gary Steinberg, MD. With the approval of gemcitabine intravesical system ...